Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
tickr was created to give people the power to invest in companies. Designed for the next generation, the company specialises in Impact Investing. tickr has 1,000s of users across both iOS and Android platforms. 70% of tickr's users are first-time investors, and about 90% are under the age of 40. tickr has won Tech Nation Rising Stars Award in 2019. It is also a part of the Wealthtech 100 in April 2019-annual list. With the proceeds, tickr will continue to build its user base, focus on product improvement and team expansion.
days to go:
Expired
investment:
£1,147,481
Personalised Co. is a nutrition company on a mission to help as many people as possible reach their health and wellbeing goals by making supplements accessible and affordable. The company asserts that it provides personalised nutritional products to its consumers. Customers are required to take a quiz on the company's portal, based on which, the company's custom-built algorithm creates nutritionist-approved solutions tailored to the specific needs and goals of each customer. Personalised Co. has delivered 270,000 daily vitamin sachets till date. The company has also raised £192,000 from private investors and its first crowdfunding campaign in 2019. It achieved its milestone month in April 2020 earning £48,000 in revenue and delivering over 1,700 personalised vitamins and protein orders. The company will use the investment to level-up its operations, expand its product line and develop its companion-application.
days to go:
Expired
investment:
£401,417
DeadHappy is a digital-first life insurance provider that aims to disrupt the £3.7 billion life insurance market. The company claims that traditional life insurance is complex, expensive, and inflexible. DeadHappy argues that it can offer customers a cheap, flexible and enjoyable alternative. It has developed a unique pay-as-you-go life insurance product with a rolling 10 year guarantee of cover. A simple sign-up process allows customers to answer only 4 medical questions & obtain cover in under 5 minutes, on-line, via their mobile phone. The company's proprietary Deathwish Platform enables customers to personalise their life insurance by creating ‘Deathwishes’. In 2020, DeadHappy reached 120,000+ total deathwishes and has sold 7,800+ total life insurance policies. The company will use 35% of the investment for company growth, 30% for technology development, 20% for product development, and 15% to build partnerships.
days to go:
Expired
investment:
£2,703,820
Verto Homes have created the Zero Carbon Smart Home. These homes create and store their own clean energy from the sun, they automatically know when and where light heat and shade are needed and they manage the energy they use so efficiently that their energy bills are almost 0.
days to go:
Expired
investment:
£1,389,280
Agile Store Builder allows you create your very own worldwide network of multiple stores by country, language, domain and product. These are all collectively managed in one system. You can also create stores for partners and affiliates to sell your products on a commission basis.
days to go:
Expired
investment:
£261
Alter Vego (AV) aims to create an extensive range of plant-based, customisable supplements. The company asserts that its production process is sustainable. It starts by creating a vegan protein base blend from ingredients such as pea, hemp, quinoa and brown rice that is ethically sourced and produced. It then develops daily sachets that contain Omega 3, B12, D3, K1, digestive enzymes, and probiotics to complement the base blend. AV argues that the sachets provide 100% of a user's Recommended Dietary Allowance (RDA) over any pre-mixed bulk blend. It aspires to become a contender in the global nutrition sector worth $702 billion. AV will use the investment for manufacturing and marketing its products across the UK.
days to go:
Expired
investment:
£46,455
